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Kinetochores are specialised multi-protein complexes that play a crucial role in maintaining 
genome stability 1. They bridge attachments between chromosomes and microtubules during 
mitosis and they activate the spindle assembly checkpoint (SAC) to arrest division until all 
chromosomes are attached 2. Kinetochores are able to efficiently integrate these two processes 
because they can rapidly respond to changes in microtubule occupancy by switching localised SAC 
signalling ON or OFF 2-4. We show that this responsiveness arises because the SAC primes 
kinetochore phosphatases to induce negative feedback and silence its own signal. Active SAC 
signalling recruits PP2A-B56 to kinetochores where it antagonises Aurora B to promote PP1 
recruitment. PP1 in turn silences the SAC and delocalises PP2A-B56. Preventing or bypassing key 
regulatory steps demonstrates that this spatiotemporal control of phosphatase feedback underlies 
rapid signal switching at the kinetochore by; 1) allowing the SAC to quickly transition to the ON 
state in the absence of antagonising phosphatase activity, and 2) ensuring phosphatases are then 
primed to rapidly switch the SAC signal OFF when kinetochore kinase activities are diminished by 
force-producing microtubule attachments. 
 
The spindle assembly checkpoint (SAC) is globally activated at mitotic entry and only extinguished 
when all kinetochores have established force-producing microtubule attachments 2, 3. At each 
individual kinetochore however, the SAC responses are much more dynamic. Here, localised SAC 
signalling switches rapidly between the ON and OFF states depending on microtubule occupancy 2-6. 
Exactly how kinetochores manage to achieve this rapid signal switching remains unknown. To 
address this we initially focussed on characterising the kinetochore phosphatases responsible for 
SAC silencing in mammalian cells. We performed a targeted screen with siRNAs to 222 individual 
phosphatase subunits to identify those that regulate mitotic exit in mammalian cells. 48 hours after 
siRNA transfection, cells were synchronised in mitosis using the microtubule poison nocodazole, 
after which mitotic exit was forced by the small molecule MPS1 inhibitor reversine 7 for 1 hour. The 
fraction of cells remaining in mitosis was quantified and eight of the top 14 siRNAs that delayed 
 3 
mitotic exit targeted subunits of PP1 and PP2A-B56 (Fig.1a and Supplementary Table.1). PP1 is 
known to silence the SAC in S. pombe, S. cerevisiae and C. elegans 8-12 and therefore we initially 
focussed on PP2A-B56, a centromere- and kinetochore-localised phosphatase that maintains sister 
chromatid cohesion, regulates kinetochore-microtubule attachments and controls chromosome 
movements 13-15. To ensure that microtubule-associated functions of PP2A-B56 could not interfere 
with our analysis of SAC silencing, all subsequent experiments were performed in the presence of 
nocodazole (unless stated otherwise). A non-overlapping pool of siRNAs that collectively target all 
PP2A-B56 subunits 14 (hereafter referred to as B56) delayed mitotic exit following MPS1 inhibition in 
nocodazole (Fig.1b). Live monitoring of endogenous Cyclin B1 levels 16 showed that B56 depletion 
prevented efficient APC/C activation following MPS1 inhibition (Fig.1c). This indicated that PP2A-B56 
depletion did not simply delay mitotic exit, but in fact prevented SAC silencing. PP2A-B56 has 
recently been shown to localise to the outer kinetochore via interaction with a short phosphorylated 
motif in BUBR1 (termed KARD) 17-19. We found that all B56 isoforms that we tested (B56, , 1, 3, 
) localised to the centromere/kinetochores regions of mitotic chromosomes, with some more 
clearly enriched on kinetochores than others (B561, 3, ; Supplementary Fig.1a). We next deleted 
the B56 binding motif from BUBR1 (BUBR1∆KARD; Supplementary Fig.1b-d), which specifically 
abolished B56 kinetochore localisation (Fig.1d, e and supplementary fig.1e), and delayed mitotic exit 
following MPS1 inhibition with either reversine (Fig.1f) or the distinct inhibitor AZ-3146 20 
(Supplementary Fig.1f). These delays were accentuated by concomitant B56 depletion, which even 
allowed cells to mount a prolonged arrest with a high dose of reversine or AZ-3146 (Supplementary 
Figs.1g-j). This was unrelated to effects on centromeric PP2A-B56 because SGO1 depletion caused 
mitotic arrest due to reduced centromeric PP2A and loss of sister chromatid cohesion, as expected 
13, but did not affect SAC silencing following MPS1 inhibition with reversine (Supplementary Fig.1k-
m). Collectively, these data demonstrate that outer-kinetochore-localized PP2A-B56 is essential for 
SAC silencing in human cells. 
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PP1 is required for SAC silencing in C. elegans, S. pombe and S. cerevisiae 8-12. PP1 and PP2A-B56 are 
known to bind to adjacent regions in the kinetochore scaffold KNL1: PP1 binds to conserved SSILK 
and RVSF motifs in the N-terminus of KNL1 21 and PP2A-B56 binds indirectly (via BUBR1) to MELT-like 
motifs scattered across the N-terminal half of KNL1 17-19, 22-24. BUBR1/PP2A-KNL1 interactions are 
promoted by MPS1-dependent phosphorylation of the MELT-like motifs 25-27 while PP1-KNL1 
interaction is repressed by Aurora B-dependent phosphorylation of the SSILK/RVSF motifs 21 (Fig.2a). 
We hypothesised that PP2A-B56 may antagonise phosphorylation of the SSILK/RVSF motifs to induce 
PP1 kinetochore recruitment and SAC silencing. In agreement, PP2A-B56 depletion or BUBR1∆KARD 
expression elevated basal phosphoryation of the RVSF (p-Ser60) and SSILK (p-Ser24) motifs in 
nocodazole (Fig.2b, c and Supplementary Fig.2a-d), and this correlated with decreased kinetochore-
PP1 (Fig.2d-g). Moreover, Aurora B inhibition with ZM-447439 or mutation of the SSILK/RVSF 
phosphorylation sites in KNL1 (KNL12SA) 21 (Supplementary Fig.2e, f) allowed efficient mitotic exit in 
BUBR1∆KARD-expressing or B56-depleted cells (Fig.2h, i and Supplementary Fig.3a-f). Conversely, 
mimicking Aurora B-dependent SSILK/RVSF phosphorylation sites (KNL12SD) or mutating the RVSF 
motif (KNL14A) 21 reduced kinetochore PP1 (Fig.2a, j, k and Supplementary Fig.2e, f), delayed mitotic 
exit following MPS1 inhibition in nocodazole (Fig.2l), and preserved cellular levels of the Mitotic 
Checkpoint Complex (MCC; the SAC effector) (Supplementary Fig.3g). The prolonged mitotic arrest in 
these cells also depended on MAD2 and BUBR1, which confirms that it was caused by persistent SAC 
activity (Supplementary Fig.3h). BUBR1∆KARD-expression did not significantly affect activity of relevant 
kinetochore kinases (MPS1, CDK1, Aurora B) (Supplementary Fig.4a). These data demonstrate that 
kinetochore-PP1 drives SAC silencing and that the balance between Aurora B and PP2A-B56 controls 
PP1 recruitment. It is of interest to note that other established kinetochore functions of PP2A-B56 14 
may at least partially operate via PP1, because expression of KNL12SA also partially restored 
chromosome alignment defects upon B56 depletion and rescued the corresponding rise in Aurora B 
activity (Supplemental Fig.4b, c).  
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The PP1 binding site in KNL1 lies in close proximity to the MELT-like motifs that are phosphorylated 
by MPS1 21, 25-27, contributing to kinetochore recruitment of essential SAC effectors such as MAD1, 
MAD2, BUB1 and BUBR1 22, 24, 28. Expression of KNL12SD or KNL14A to reduce kinetochore PP1, 
elevated basal MELT motif phosphorylation and limited MELT dephosphorylation following MPS1 
inhibition in nocodazole (Fig.3a, b and Supplementary Fig.4d). This correlated with an increase in 
kinetochore BUB1 and a corresponding increase in MAD1 (Supplementary Fig.4e-j). KNL12SD or 
KNL14A similarly prevented MELT dephosphorylation and BUB1 loss at metaphase as well 
(Supplementary Fig.4k, l). Conversely, expression of KNL12SA to enhance kinetochore PP1 (Fig.2j, k), 
decreased basal MELT phosphorylation and inhibited kinetochore association of BUB1 (Fig.3a, b and 
Supplementary Fig.4g, h). Thus, in agreement with other studies 24, 26, KNL1-bound PP1 antagonises 
MPS1 signalling at kinetochores. It is important to note that other pools of PP1 clearly exist at 
kinetochores (Fig.2j, k), as observed previously by others 29, but these cannot potently regulate SAC 
silencing given the strong SAC silencing defect in KNL12SD and KNL14A cells (Fig.2l).  
 
Since MELT phosphorylation is crucial for BUBR1 kinetochore binding 22, 24 our data suggested that 
PP1 may remove BUBR1-associated PP2A-B56 from kinetochores. In support of this, expression of 
KNL12SD or KNL14A elevated kinetochore PP2A-B56, while KNL12SA decreased it (Fig.3c, d). 
Interestingly, Aurora B inhibition or KNL12SA expression inhibited phosphorylation of Ser670 within 
the KARD of BUBR1, which is required for efficient binding of PP2A-B56 to BUBR1 17, 18, while KNL12SD 
and KNL4A expression elevated KARD phosphorylation (Fig.3e-h). The various KNL1 mutants did not 
significantly affect kinetochore activity of the relevant kinases (Supplementary Fig.4m), thus we 
conclude that kinetochore-PP1 promotes removal of kinetochore-PP2A-B56 by dephosphorylating 
the MELT and KARD motifs. Importantly, KNL12SA expression was also able to inhibit the rise in MELT 
and KARD phosphorylation seen following PP2A-B56 depletion (Fig.3i, j), confirming that PP2A-B56 
regulates SAC silencing and its own recruitment principally via PP1. Although incomplete KNL1 
knockdown/replacement (Supplementary Fig.2c) is likely to contribute to the modest rise in 
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MELT/KARD phosphorylation in KNL12SA cells (Fig.3j), we cannot formally exclude a small additional 
effect of PP2A-B56 on the MELT/KARD motifs directly, as suggested recently by others 30. We 
consider this unlikely, however, since high kinetochore B56 in cells expressing KNL14A or KNL12SD 
(Fig.3c, d) could not prevent an increase in MELT/KARD phosphorylation in those cells (Fig.3a, b, g, h) 
and could not remove BUB1 from kinetochores following 30 min reversine treatment 
(Supplementary Fig.4f) . These data do pose an interesting biological conundrum however; namely 
how do PP1 and PP2A-B56 achieve any level of specificity when they display little (if any) substrate 
preference in vitro 31, 32, yet they localise to an almost identical molecular space in vivo and thus their 
respective substrates are in very close proximity? We hypothesise that dephosphorylation of their 
own recruitment motifs is restricted because 1) PP1 only binds KNL1 when the SSILK/RVSF motifs are 
already dephosphorylated, and 2) the kinetochore-localisation of PP2A-B56 requires interaction 
between p-MELT/BUB3 23 and p-KARD/PP2A 17, 18, thus potentially masking these motifs from 
dephosphorylation when PP2A-B56 is co-localised. A requirement for PP1 docking to the KNL1 N-
terminus to allow dephosphorylation of the adjacent MELT/KARD motifs may also help to explain 
how other pools of kinetochore PP1 can exist that do not regulate SAC silencing (see KNL12SD and 
KNL14A cells in Fig.2j-l), but do control other process such as kinetochore-microtubule attachment 29.  
 
Collectively, these data demonstrate spatial negative feedback between two kinetochore 
phosphatases; PP2A-B56 promotes the recruitment of PP1 to kinetochores, which subsequently 
antagonises the localisation of PP2A-B56. MPS1-dependent MELT phosphorylation thus both 
initiates the SAC signal and at the same time primes the silencing of that signal by recruiting PP2A-
B56. We hypothesised that such a system could impart responsiveness to the SAC (i.e. the ability to 
switch rapidly between the ON and OFF states): When the SAC is OFF Aurora B is predicted to 
phosphorylate the SSILK/RVSF motifs unopposed, thereby repressing PP1 kinetochore binding and 
allowing efficient MPS1-dependent MELT phosphorylation. Conversely, when the SAC is ON PP2A-
B56 is predicted to compete with Aurora B to enhance PP1 kinetochore binding, thus ensuring that 
 7 
the SAC is primed to silence rapidly when kinetochore Aurora B and MPS1 activities diminish upon 
microtubule attachment/tension 33, 34 (see Fig.4a for model). 
 
To test this hypothesis we first monitored key phosphorylation sites on KNL1 during mitotic entry in 
nocodazole, when the SAC signal is OFF and needs to quickly establish. RVSF and MELT motif 
phosphorylation were maximal during prophase of nocodazole-treated cells, and declined in early 
mitosis (Fig.4b, c). This decline, which still occurred in a dose of nocodazole known to prevent 
residual microtubules (3.3 M 35; Supplementary Fig.5a), was associated with a corresponding 
decrease in SAC components at the kinetochore and coincided with elevated phosphorylation of the 
BUBR1 KARD and kinetochore recruitment of PP2A-B56 and PP1 (Fig.4b, c). Expression of BUBR1∆KARD 
halted the decline in RVSF and MELT phosphorylation (Fig.4d and Supplementary Fig.5b) confirming 
that kinetochore-PP2A-B56 antagonises Aurora B to induce negative feedback specifically following 
progression into prometaphase. If Aurora B effects are antagonised earlier, by direct Aurora B 
inhibition or KNL12SA expression, then MELT phosphorylation and SAC protein accumulation are both 
delayed (Fig.4e, f). Thus, the shielding of prophase kinetochores from PP2A-B56-mediated feedback, 
which is likely due to exclusion of BUBR1 from the nucleus, allows Aurora B to phosphorylate the 
SSILK/RVSF motifs unopposed and permit rapid initiation of SAC signalling. Furthermore, 
phosphorylation of the BUBR1 KARD 17, 18) was also markedly reduced by Aurora B inhibition or 
KNL12SA expression (Fig.4e, f). Thus, negative feedback from PP2A-B56 is also restricted during early 
mitosis until the SSILK/RVSF motifs are phosphorylated and PP1 is removed. Collectively, these data 
demonstrate that the absence of negative feedback from kinetochore phosphatases allows rapid 
establishment of SAC signalling during early mitosis.  
 
The decline in RVSF and MELT phosphorylation in early and late mitosis was associated with PP2A-
B56/PP1 recruitment and a decrease in SAC components at kinetochores (Fig.4b, c). We therefore 
examined whether elevated phosphatase levels at kinetochores during mitosis may prime the SAC 
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for rapid silencing when Aurora B and MPS1 activities drop (for instance by tension-producing 
microtubule attachments). To this end, BUBR1WT and BUBR1∆KARD cells were arrested in nocodazole 
and a metaphase-like state was mimicked by combined addition of Aurora B and MPS1 inhibitors. 
We opted for this approach to circumvent indirect effects on SAC silencing by PP2A- and PP1-
dependent regulation of kinetochore-microtubule attachments 14, 17, 21. While Aurora B and MPS1 
inhibition caused rapid silencing of the SAC signal in control cells, dephosphorylation of the RVSF and 
MELT motifs (Fig.5a), and loss of kinetochore BUBR1 (Fig.5b), were both delayed by BUBR1∆KARD 
expression. This effect was even more pronounced by additional depletion of B56 (Fig.5c-e), which is 
likely to reflect a synergistic effect on kinetochore-B56 levels because targeting the centromeric pool 
of B56 directly (by SGO1 depletion) did not delay mitotic exit (Supplementary Fig.5c). Thus physical 
coupling between the SAC signal and PP2A-B56 ensures that kinetochore SAC signalling can be 
silenced rapidly following microtubule attachment/tension.  
 
In summary, we show here that SAC responsiveness is due to localized negative feedback between 
PP1 and PP2A-B56. This ensures that the SAC signal can be switched ON rapidly, after which the SAC 
signal primes its own silencing to ensure kinetochores can rapidly switch SAC signalling OFF when 
needed. Once the SAC signal is silenced, negative feedback is locally uncoupled due to removal of 
PP2A-B56, which is predicted to return kinetochores to a state that permits rapid SAC initiation if 
required. Therefore, SAC responsiveness may not only be important during prophase and metaphase 
(when the SAC must be globally switched ON and OFF, respectively) but also during prometaphase 
when error-correction is continuously detaching chromosomes and re-establishing the SAC signal at 
individual kinetochores. The regulated negative feedback that we show here may be a common 
mechanism used by signalling networks to elicit responsiveness: the key is that the activating 
stimulus (Aurora B and MPS1 in our example) primes negative feedback, but then restricts this 
feedback until the appropriate time (Fig.5f). This is analogous to a similar feedback network at 
mitotic entry, when Cyclin B/CDK1 primes its own degradation by activating the APC/C, but then 
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initiates the SAC to restrict this degradation until chromosome alignment is complete 36-39. The result 
is an active APC/C that can rapidly degrade Cyclin B as soon as the brake on negative feedback is 
released at metaphase. It will be important to determine whether such network topology is 
repeated in other signalling processes that must be similarly responsive. 
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Figure legends 
Figure 1. Kinetochore PP2A-B56 is required for SAC silencing. (a) Mitotic index screen of U2OS cells 
that were transfected with a panel of siRNAs to phosphatase subunits, arrested in prometaphase 
with nocodazole and subsequently treated with reversine (1 µM) for 1h. Graph shows each targeted 
gene ranked according to the mean fraction of mitotic cells persisting following MPS1 inhibition. (b) 
Time-lapse analysis of duration of mitotic arrest in nocodazole-treated Flp-in HeLa cells transfected 
with mock or a pool of PP2A-B56 siRNAs. Cells entered mitosis in the presence of reversine (500 
nM). (c) Time-lapse imaging of endogenous Cyclin B-EYFP fluorescence in nocodazole-treated U2OS 
cells, transfected with mock siRNA or a pool of PP2A-B56 siRNAs, and treated with reversine (1 µM) 
at the indicated time. (d) Representative images and (e) quantification of kinetochore-localised HA-
B561 in nocodazole-arrested LAP-BUBR1
WT or LAP-BUBR1KARD cells. (f) Time-lapse analysis of 
duration of mitotic arrest in nocodazole-treated LAP-BUBR1WT or LAP-BUBR1KARD-expressing cells 
that entered mitosis in the presence of reversine (500nM). Graphs in b and f show cumulative data 
from 50 cells from one experiment, which is representative of 3 independent experiments. Insets 
show magnifications of the boxed regions. Bar graph displays mean fold-change in kinetochore 
intensities (±SD) relative to mock treated LAP-BUBR1WT cells from 3 independent experiments with 
at least 10 cells quantified for each condition per experiment (see Supplementary Table 2). **** 
p<0.0001 (student t-test, unpaired).  
Figure 2. PP2A-B56 regulates the kinetochore-recruitment of PP1 to control SAC silencing. (a) 
Schematic representation of the various KNL1 mutants used in this study. (b) Representative images 
and (c) quantification of immunolocalization of pRVSF(Ser60)-KNL1 and kinetochores (CENP-C) in 
nocodazole-treated LAP-BUBR1WT or LAP-BUBR1KARD-expressing cells treated with mock or PP2A-B56 
siRNA, as indicated. (d, e) Representative images and (f, g) quantification of RFP-PP1 localisation in 
nocodazole-arrested Flp-in HeLa cells treated with mock or B56 siRNA, or expressing LAP-BUBR1WT or 
LAP-BUBR1KARD, as indicated. (h) Time-lapse analysis of duration of mitotic arrest in nocodazole-
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treated LAP-BUBR1WT or LAP-BUBR1KARD-expressing cells that entered mitosis in the presence of ZM-
447439 (2 µM) and a low dose of reversine (125 nM). (i) Time-lapse analysis of duration of mitotic 
arrest in nocodazole-treated Flp-in HeLa cells expressing KNL1WT or indicated KNL1 mutants and 
transfected B56 or mock siRNA. Cells entered mitosis in the presence of an intermediate dose of 
reversine (250 nM). (j) Representative images and (k) quantification of RFP-PP1 localisation in 
nocodazole-treated Flp-in HeLa cells expressing KNL1WT or indicated KNL1 mutants. (l) Time-lapse 
analysis of duration of mitotic arrest in in Flp-in HeLa cells expressing KNL1WT or indicated KNL1 
mutants. Cells entered mitosis in the presence of reversine (500 nM). Graphs in h, i and l show 
cumulative data from 50 cells from one experiment, which is representative of 3 independent 
experiments. Insets show magnifications of the boxed regions. Bar graphs display mean fold-change 
in kinetochore intensities (±SD) relative to mock treated LAP-BUBR1WT cells (c, f, g) or LAP-KNL1WT 
cell (k), from 3 (f, g) or 4 (c, k) independent experiments with at least 10 cells quantified for each 
condition per experiment (see Supplementary Table 2). Asterisks indicate significance (student t-
test, unpaired). *: p<0.05, **: p<0.01, ***:p<0.001, ****: p<0.0001. DNA (DAPI) is shown in blue. 
Bars, 5 μm. 
Figure 3. PP1 controls silencing of the SAC signal and removal of kinetochore PP2A-B56. (a) 
Representative images and (b) quantification of relative kinetochore intensities of indicated antigens 
in nocodazole-arrested Flp-in HeLa cells expressing KNL1WT or indicated KNL1 mutants. Cells were 
treated, as indicated, with nocodazole, MG132, DMSO and/or reversine (500 nM). (c) Representative 
images and (d) quantification of relative kinetochore intensities of indicated antigens in nocodazole-
arrested Flp-in HeLa cells expressing KNL1WT or indicated KNL1 mutants. (e) Representative images 
and (f) quantification of relative kinetochore intensities of indicated antigens in nocodazole-arrested 
Flp-in HeLa cells that entered mitosis in the presence of DMSO or the Aurora B inhibitors ZM-447439 
(2 M) or hesperadin (100 nM). (g-j) Representative images (g, i) and quantification (h, j) of relative 
kinetochore intensities of indicated antigens in nocodazole-arrested Flp-in HeLa cells expressing 
KNL1WT or indicated KNL1 mutants. Cells in i, j were treated with mock or PP2A-B56 siRNA, as 
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indicated. Insets show magnifications of the boxed regions. Bar graphs display mean fold-change in 
kinetochore intensities (±SD) relative to mock treated KNL1WT (b, d, h, j) or DMSO-treated Flp-in 
HeLa (f) cells, from 3 (b, d, h) or 4 (f, j) independent experiments with at least 10 cells quantified for 
each condition per experiment (see Supplementary Table 2). Asterisks indicate significance (student 
t-test, unpaired). *: p<0.05, **: p<0.01, ****: p<0.0001. DNA (DAPI) is shown in blue. Bars, 5 μm. 
Figure 4. Lack of phosphatase feedback during prophase allows rapid initiation of the SAC signal. 
(a) Schematic model for responsive SAC signalling at kinetochores. When the SAC is OFF (early 
prophase) signalling can be initiated rapidly due to unopposed kinase activity. When the SAC is ON 
(prometaphase) negative feedback is primed to silence, but then restricted by Aurora B activity. 
When kinase activities diminish (metaphase), phosphatases are primed to rapidly extinguish the SAC 
signal. (b) Representative images and (c) quantifications of relative kinetochore intensities of 
indicated antigens from nocodazole-treated Flp-in HeLa cells. Different mitotic phases where 
determined by nuclear morphology with early mitosis defined as dispersed lightly condensed 
chromatin and late mitosis as highly condensed chromatin balls typical of nocodazole-arrested cells. 
Insets display magnifications of the boxed regions. (d-f) Quantification of relative kinetochore 
intensities of indicated antigens from nocodazole-treated Flp-in HeLa cells following (d) endogenous 
BUBR1 knockdown and re-expression of LAP-BUBR1WT or LAP–BUBR1KARD, (e) DMSO or ZM-447439 
(2M) treatment before mitotic entry, or (f) endogenous KNL1 knockdown and re-expression of LAP-
KNL1WT or LAP–KNL12SA. All kinetochore intensities are relative to the maximum signal in each 
experiment, except in d, which are relative to the prophase signal in LAP-BUBR1WT cells. At least 10 
cells were quantified for each condition per experiment and quantifications show the mean data 
(±SD) from 3-5 independent experiments (see Supplementary Table 2 for the specific n number for 
each treatment). Prophase (Pro), early mitosis (EM), late mitosis (LM). Asterisks indicate significance 
(student t-test, unpaired). NS: not significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. 
Bars, 5 μm. 
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Figure 5. The priming of phosphatase-mediated feedback in prometaphase allows rapid SAC 
silencing. (a) Quantification of relative kinetochore intensities and representative images of pRVSF- 
and pMELT-KNL1 in LAP-BUBR1WT or LAP–BUBR1KARD-expressing cells, arrested in prometaphase 
with nocodazole and MG132, and treated with reversine (1 µM) and ZM-447439 (2 µM) for the 
indicated times. (b) Quantification of relative LAP-BUBR1 kinetochore intensities from time-lapse 
images of LAP-BUBR1WT or LAP–BUBR1KARD cells treated as in a.  (c, d) As in a, b except in LAP–
BUBR1KARD cells depleted of PP2A-B56 and LAP-BUBR1WT treated with mock siRNA. (e) 
Representative images LAP-BUBR1 localisation from quantifications shown in d. (f) Schematic model 
of regulated negative feedback. MELT phosphorylation installs negative feedback (via PP2A-B56 
recruitment), but Aurora B restricts this feedback by inhibiting PP1 recruitment. In (a, c) At least 10 
cells were quantified for each condition per experiment and quantifications show the mean 
kinetochore intensities (±SD), relative to the 0 min timepoint in LAP-BUBR1WT cells, from 3 
independent experiments (see Supplementary Table 2). In (b, d) at least 15 cells were quantified for 
each cell line per experiment and quantifications show the mean data (±SD), relative to the 0 min 
timepoint, from 3 independent experiments. Asterisks indicate significance (student t-test, 
unpaired). NS: not significant, **: p<0.01, ***: p<0.001. Bars, 5 μm 
Methods 
Cell culture and reagents 
U2OS cells, Cyclin B-EYFP U2OS cells 16 and HeLa Flp-in cells (a gift from S. Taylor), stably expressing a 
TetR, were cultured in DMEM supplemented with 9% tetracycline-approved FBS, 50 µg/ml 
penicillin/streptomycin and 2 mM L-glutamine. All cell lines were routinely screened (every 4-8 
weeks) to ensure they were free from mycoplasma contamination. All HeLa Flp-in cells stably 
expressing a doxycycline-inducible construct were derived from the HeLa Flp-in cell line by 
transfection with pCDNA5/FRT/TO vector (Invitrogen) and pOG44 (Invitrogen) and cultured in the 
same medium but containing 200 µg /ml hygromycin and 4 µg /ml blasticidin. The HeLa Flp-in RFP-
PP1γ D10 cell line, stably and constitutively expressing RFP-PP1γ, was created by transfection of 
HeLa Flp-in cells with pCDNA3-puro-2xRFP-PP1γ, puromycin selection and clonal isolation. Double 
positive LAP-KNL1/RFP-PP1γ cell lines were derived from this background by genomic integration of 
pCDNA5-LAP-KNL1 plasmids, as described above. HeLa Flp-in cells stably expressing doxycycline-
inducible LAP-BUBR1WT or LAP-BUBR1KARD were infected twice with pSuperior retrovirus expressing 
a doxycycline-inducible short hairpin targeting BUBR1 (AGATCCTGGCTAACTGTTCtctcttgaa 
GAACAGTTAGCCAGGATCT). Stable polyclonal cell lines were generated following puromycin 
selection. To induce protein expression in the inducible cell lines, 1 µg/ml doxycycline was added for 
≥36 h. Thymidine (2 mM), nocodazole (830 nM), MG132 (10 µM), reversine and puromycin were all 
obtained from Sigma-Aldrich. Hygromycin was purchased from Roche, ZM-447439 from Tocris 
Bioscience, Hesperadin from Selleck Chemicals, Blasticidin from PAA Laboratories. AZ-3146 was from 
Axon. Purified MPS1 was purchased from Life Technologies (PV3792). 
 
Plasmids and cloning 
pOG44 (Invitrogen) encodes a FLP recombinase expression vector. HA-PP2A-B56 plasmids were 
described previously (addgene plasmids 14532-14537; deposited by D. Virshup). pCDNA5-LAP-
BUBR1WT, encoding and N-terminally LAP-tagged and siRNA-resistant wild type BUBR1, and pCDNA5-
LAP-BUBR1ΔKARD, lacking amino acids 647-697, were subcloned from the respective pLAP-BUBR1 
constructs 17. GST-KNL1-M3 and GST-KNL1-A3, which contain a KNL1818-1051 fragment encompassing 3 
MELT motifs, were described previously 22. pCDNA5-LAP-KNL1WT encodes full length, N-terminally 
LAP-tagged and siRNA-resistant wild type KNL1 (modified codons 258 and 259) and was created by 
digestion of pEYFP-LAP-KNL1WT (a gift from I. Cheeseman) with XhoI and HpaI to isolate the full 
length KNLWT cassette, which was ligated into the XhoI and PmeI sites of pCDNA5/FRT/TO 
(Invitrogen). An N-terminal LAP-tag was introduced by subcloning the LAP-tag cassette from 
pCDNA3-LAP-MPS1Δ200  (Ref 34) into the KpnI and XhoI sites of the resulting plasmid. pCDNA5-LAP-
KNL12SA and pCDNA5-LAP-KNL12SD were created by subcloning the KNL1 N-terminus from pEYFP-LAP-
KNL12SA and pEYFP-LAP-KNL12SD (also gifts from I. Cheeseman) into pCDNA5-LAP-KNL1WT via the XhoI 
and EcoRV restriction sites. pCDNA5-LAP-KNL14A was created by site-directed mutagenesis of 
pCDNA5-LAP-KNL1WT.  pCDNA3-puro-2xRFP-PP1γ was created by PCR of a tandem of tagRFP inserts 
from pPA-TAGRFP-H2B (Evrogen) and ligation into the BamHI and NotI restriction sites of the N-
terminal LAP-tag of pLAP-PP1γ (a gift from I. Cheeseman). The resulting RFP-RFP-PP1γ cassette was 
subcloned into the BamHI and EcoRI restriction sites of pCDNA3-puro. The pSuperior BUBR1 
inducible-short hairpin vector was generated by annealing synthesised primers and subsequent 
ligation into the pSuperior vector, as per manufacturer’s instructions (Oligoengine). 
 
Phosphatase screen 
U2OS cells were seeded in 96 well plates at 20% confluency, and transfected with 20 nM siRNA using 
Hiperfect (20nM final of four pooled siRNAs from a dharmacon ON-TARGETplus siRNA library 
targeting human phosphatases; GU103700). After 48 hours, cells were treated with nocodazole and 
allowed to accumulate in prometaphase for 16 hours. Finally, cells were driven out of mitosis by the 
addition of 1 µM of reversine for 1 hour. Cells were fixed with 4% PFA for 45 min at room 
temperature, washed with PBS and blocked with 2% BSA, supplemented with 0,2% TX100, for at 
least 1 hour. Cells were stained for pSer10-Histone-H3 to identify mitotic cells and DAPI. Image 
acquisition was performed using a Cellomics ArrayScan VTI (Thermo Scientific) using a 10× 0.50NA 
objective. Image analysis was performed using Cellomics ArrayScan HCS Reader (Thermo Scientific). 
In short, cells were identified on the basis of DAPI staining and they were scored as `mitotic' if the 
pSer10-Histone-H3 staining reached a pre-set threshold.  
 
Knockdown and reconstitution experiments with LAP-KNL1 and LAP-BUBR1WT/KARD 
For all KNL1 and BUBR1 mutant experiments, the endogenous mRNA was knocked down and 
replaced with an siRNA-resistant mutant using HeLa Flp-in cells, as stated below. For knockdown and 
reconstitution of KNL1 in HeLa Flp-in cells, cells were transfected with 20 nM KNL1 or mock siRNA 
and, in some experiments, 20 nM additional mock, MAD2, BUBR1 or B56 siRNA for 16 h after which 
the cells were arrested in early S phase for 24 h by addition of thymidine. Subsequently, cells were 
release from thymidine for 8-10 h and arrested by the addition of nocodazole and (for 
immunolocalisation experiments) subsequently treated with MG132 to prevent mitotic exit and (in 
some experiments) Aurora B or MPS1 inhibitors or DMSO for 20-30 minutes. LAP-KNL1 expression 
was induced by the addition of doxycycline during and following the thymidine block. For 
knockdown and reconstitution of BUBR1WT/KARD, stable cells were induced with doxycycline 
overnight (to simultaneously knockdown endogenous BUBR1 and induce the ectopic forms), then 
arrested in thymidine and doxycycline for a further 24 hours before release from thymidine for 8-10 
h into nocodazole and doxycycline (for immunolocalisation or live imaging experiments). 
 
Transfections and siRNA 
Plasmids were transfected into Flp-in HeLa cells using Fugene HD (Promega) according to the 
manufacturer’s instructions. siRNAs used in this study were as follows: si-MPS1, 5’-
GACAGAUGAUUCAGUUGUA-3’ (custom; Thermo Fisher Scientific); si-mock (Luciferase GL2 duplex; 
D-001100-01-20; Thermo Fisher Scientific); si-KNL1, 5’-GCAUGUAUCUCUUAAGGAA-3’ (CASC5#5; J-
015673-05; Thermo Fisher Scientific); si-BUBR1, 5’-AGAUCCUGGCUAACUGUUC-3’ (custom; Thermo 
Fisher Scientific); si-MAD2, 5’-UACGGACUCACCUUGCUUG-3’ (custom; Thermo Fisher Scientific); si-
SGO1, 5’-GAUGACAGCUCCAGAAAUU-3’ (custom; Thermo Fisher Scientific). The B56 family siRNA 
pool was composed of 5 individual siRNAs that together targeted all B56 isoforms as described 
previously 14. The siRNAs were mixed at an equimolar ratio and transfected at a total concentration 
of 20 nM. The siRNAs used (all from Thermo Fisher Scientific) were B56α (PPP2R5A), 5’-
UGAAUGAACUGGUUGAGUA-3’; B56β (PPP2R5B), 5’-GAACAAUGAGUAUAUCCUA-3’; B56γ (PPP2R5C), 
5’-GGAAGAUGAACCAACGUUA-3’; B56δ (PPP2R5D), 5’-UGACUGAGCCGGUAAUUGU-3’; B56ε 
(PPP2R5E), 5’-GCACAGCUGGCAUAUUGUA-3’. All siRNAs were transfected using HiPerFect (Qiagen) 
at 20 nM according to the manufacturer’s instructions.  
 
Immunoprecipitation and immunoblotting 
Flp-in HeLa cells were treated with thymidine for 24 h and subsequently released into nocodazole 
for 14 h. Cells were treated with reversine (500 nM, unless stated otherwise) or DMSO and MG132 
to prevent mitotic exit for 1 hour. Mitotic cells were isolated by mitotic shake off and lysed in lysis 
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% TX-100, 2mM MgCl2, 5 mM EDTA, 1 mM Na3VO4, 1 mM 
β-glycerophosphate, 1 mM NaF and complete protease inhibitor [Roche]) on ice. The cleared extract 
was incubated with 10% protein A-agarose beads (Roche)/antibody mix for 2 hours at 4°C on a 
rotating wheel. The beads were washed four times with lysis buffer. Supernatant and beads were 
processed for SDS-PAGE and the proteins were transferred to nitrocellulose membranes for 
immunoblotting. Immunoblotting was performed using standard protocols; the signal was visualized 
and analyzed on a scanner (ImageQuant LAS 4000; GE Healthcare) using enhanced 
chemiluminescence.  
 
Antibodies 
The pMELT-KNL1 antibody, directed against Thr943 and Thr1155 of human KNL1 (which have 
identical sequences), was raised in rabbits using the peptide MEIpTRSHTTALEC (Genscript). The 
antibody was used at 1:2000 dilution in the presence of nonphosphorylated peptide (1 ng/ml) in all 
experiments. The pSILK-KNL1 (pSer24-KNL1) and pRVSF-KNL1 (pSer60-KNL1) antibodies (custom 
rabbit polyclonals, characterised previously 40; gifts from Iain Cheeseman), were used at 1:2000 
dilution in the presence of a nonphosphorylated peptide (1 ng/ml) in all experiments. The pKARD 
antibody recognizes pSer670-BUBR1 (custom rabbit polyclonal) and was used at 1:2000 dilution. The 
following primary antibodies were used for immunofluorescence and/or immunoblotting at 
indicated dilutions: α-tubulin (clone B-5-1-2, T5168, Sigma-Aldrich. 1:10000), Aurora B pT232 
(Rockland; 600-401-677S. 1:4000), BUB1 (A300-373A; Bethyl. 1:2000), BUBR1 (A300-386A; Bethyl. 
1:2000), BUBR1 (custom sheep polyclonal. 1:30000), BUBR1 (clone 8G1, 05-898; Upstate/Millipore. 
1:2500), CDC20 (clone E-7, sc-13162; Santacruz Biotechnology), CENP-C (PD030; MBL. 1:5000), CENP-
T (D286-3; MBL. 1:2000), CENP-T pS47 (custom rabbit polyclonal, a gift from  I. Cheeseman 41. 
1:2000), CREST (Cortex Biochem. 1:2000), GFP (clones 7.1 and 13.1, #11814460001; Roche. 1:1000), 
GFP (clone 4E12/8; a gift from Peter Parker. 1:1000), GFP (clone LGB-1, ab291, Abcam. 1:2000), GFP 
(custom rabbit polyclonal. 1:10000), GST (clone B1-14, sc-138; Santacruz Biotechnology. 1:1000), HA 
(clone Y-11, sc-805; Santacruz Biotechnology. 1:1000), pSer10-Histone 3  (06-570, Millipore. 1:2000), 
KNL1 (ab70537, Abcam. 1:1000), MAD1 (clone BB3-8, custom mouse monoclonal, a gift from A. 
Musacchio. 1:100), MAD2 (custom rabbit polyclonal), MPS1 pThr676 (custom rabbit polyclonal. 
1:1000) 42, PP2A-B56 (clone 23, sc-136045; Santacruz Biotechnology. 1:1000), SGO1L1 (clone 3C11, 
H00151648-M01; Abnova. 1:2000), TFR (13-6890; Invitrogen. 1:2500). Secondary antibodies for 
immunofluorescence experiments were goat anti-rat Alexa Fluor 647, high-cross absorbed goat-anti-
guinea pig and anti-human Alexa Fluor 647, donkey anti-sheep Alexa Fluor 568 and goat anti-rabbit 
and anti-mouse Alexa Fluor 488 and Alexa Fluor 568 (Molecular Probes); all used at 1:1000 dilution.  
 
Live-cell imaging and immunofluorescence  
For live-cell imaging for time-lapse analysis, cells were plated in 24-well glass-bottom plates (MatTek 
Corporation), transfected, and imaged in a heated chamber (37°C and 5% CO2) using a 20x/0.5 NA 
UPLFLN objective (Olympus) on a microscope (IX-81; Olympus) controlled by Cell-M software 
(Olympus). Images were acquired using an ORCA-ER camera (Hamamatsu Photonics) and processed 
using Cell-M software.  
For live-cell imaging of LAP-BUBR1, cells were plated in 8 well chamber slides (Ibidi) in the presence 
of doxycycline (to replace endogenous BUBR1 with LAP-BUBR1). 16h later Thymidine was added for 
a further 24h before release into Leibovitz L-15 media (Invitrogen) supplemented with 10% FCS, 2 
mM L-glutamine, 100 U/ml penicillin and streptomycin, doxycycline and nocodazole. Cells arrested 
in mitosis 12h later were treated as indicated and imaged on a DeltaVision core system equipped 
with a heated 37°C chamber , with a 100x/1.40 NA U Plan S Apochromat objective using softWoRx 
software. Images were acquired using a camera (CoolSNAP HQ2; Photometrics) and processed using 
softWorx software and ImageJ (National Institutes of Health).  
For immunofluorescence, cells plated on 12-mm coverslips were pre-extracted with 0.1% Triton X-
100 in PEM (100 mM Pipes, pH 6.8, 1 mM MgCl2 and 5 mM EGTA) for 45s before fixation with 4% 
paraformaldehyde in PBS for 10 min. Coverslips were washed with PBS and blocked with 3% BSA in 
PBS for 30 min, incubated with primary antibodies for 2-4 h at room temperature or 16 h at 4°C, 
washed with PBS and incubated with secondary antibodies for an additional hour at room 
temperature. Coverslips were then incubated with DAPI for 2 min, washed and mounted using 
antifade (ProLong; Molecular Probes). For imaging of RFP-PP1γ, cells were treated as above, but 
fixed with 4% in PBS for 10 min, washed with PBS and permeabilised with 0.5% Triton X-100 for 15 
min. RFP-PP1γ was imaged by acquiring the direct fluorescence of the tagRFP moiety. For alignment 
assays, cells were treated as before, but were treated with MG132 for 30 min and fixed with 3.7% 
Shandon Zinc Formal-Fixx (Thermo Scientific) for 10 min, washed with PBS and permeabilised with 
0.5% Triton X-100 for 15 min. All images were acquired on a deconvolution system (Deltavision RT or 
Deltavision Elite; Applied Precision) with a 100x/1.40 NA U Plan S Apochromat objective (Olympus) 
using softWoRx software (Applied precision). Images are maximum intensity projections of 
deconvolved stacks. All displayed immunofluorescence images were chosen to most closely 
represent the mean quantified data. 
 
Image quantification 
For quantification of immunostainings, all images of similarly stained experiments were acquired 
with identical illumination settings and analysed using ImageJ (for experiments in which ectopic 
proteins were expressed, cells with comparable levels of exogenous protein were selected for 
analysis). An ImageJ macro was used to threshold and select all kinetochores and all chromosome 
areas (excluding kinetochores) using the DAPI and anti- kinetochore antibodies channels as 
described previously 42. This was used to calculate the relative mean kinetochore intensity of various 
proteins ([kinetochores-chromosome arm intensity (test protein)]/[kinetochores-chromosome arm 
intensity (CENP-C/CENP-T/CREST)]. For the quantification of RFP-PP1γ, a maximal intensity 
projection was generated from a selected, kinetochore-dense 2 µm region within the deconvolved 
stack to isolate the weak kinetochore signal from the cytoplasmic signal above and below the 
chromatin. Kinetochores were selected and measured as above, but RFP-PP1γ kinetochore intensity 
was calculated as a ratio of the cytosolic signal to correct for fluctuations in expression. For 
quantification of live LAP-BUBR1 kinetochore levels, two regions were selected for each time-point: 
a region encompassing all kinetochores [KT] and a region immediately adjacent in the cytoplasm 
[BG]. Relative change in kinetochore intensity ([mean KT]-[mean BG]) was calculated over time. For 
quantification of HA-B56 localisation, a line was drawn through KT pairs lying in the same Z-section 
(using ImageJ). The plot profile function was used to measure intensities across the line, after placing 
the first KT peak at a fixed 0.2 M distance from the start.  The LAP-BUBR1 channel was used to 
choose 5 random kinetochore pairs per cell for intensity measurements.  
 
Statistical tests 
Two-tailed, unpaired t-tests were performed to compare experimental groups in 
immunofluorescence quantifications (using Prism 6 software). The comparisons most pertinent for 
the conclusions are shown in the figures and legends, and a more complete set of comparisons is 
given in the source data file. 
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Supplementary legends 
Supplementary Table 1. Full results of an siRNA screen for phosphatase subunits that regulate 
mitotic exit. Mitotic index screen of U2OS cells that were transfected with a panel of siRNAs to 
phosphatase subunits, arrested in prometaphase with nocodazole and subsequently treated with 
reversine (1 µM) for 1h. Table shows each targeted gene ranked according to the mean fraction of 
mitotic cells persisting following MPS1 inhibition. Genes highlighted red were excluded due to a low 
fraction of basal mitotic arrest (< 0.5, without reversine). The gene list was selected based on a 
Dharmacon ON-TARGETplus siRNA library targeting human phosphatases (GU103700), and for each 
gene 20nM final of four pooled siRNAs was used. 
Supplementary Table 2. Source data file displaying the quantification data from all individual 
experiments.  
Supplementary Figure 1. Kinetochore PP2A-B56 promotes SAC silencing following MPS1 inhibition. 
(a) Representative images of HA-B56 isoform localisation in nocodazole-arrested mitotic cells. (b) 
Immunoblot of whole cell lysates from nocodazole-arrested LAP-BUBR1WT or LAP-BUBR1KARD cells 
two days after doxycycline addition (see methods), which is representative of 2 independent 
experiments. (c) Representative images and (d) quantifications of relative kinetochore intensities of 
indicated antigens from nocodazole-arrested LAP-BUBR1WT or LAP-BUBR1KARD-expressing cells. (e) 
Line plots displaying mean intensities (±SEM) of indicated antigens from 30 kinetochore pairs from 6 
cells, which is representative of 2 independent experiments. (f) Time-lapse analysis of duration of 
mitotic arrest in nocodazole-treated LAP-BUBR1WT or LAP-BUBR1KARD-expressing cells that entered 
mitosis in the presence of the MPS1 inhibitor AZ-3146 (2.5 µM). (g-j) Time-lapse analysis as in (f), 
except cells, additionally transfected with mock or PP2A-B56 siRNA, entered mitosis in the presence 
of the indicated concentrations of either reversine or AZ-3146. (k) Representative images and 
quantification of relative kinetochore intensity of SGO1 in nocodazole-arrested Flp-in HeLa treated 
with mock or SGO1 siRNA. Images show centromeric B56 depletion and premature loss of sister 
chromatid cohesion following SGO1 depletion. (l, m) Time-lapse analysis of duration of mitotic arrest 
in Flp-in HeLa cells transfected with mock or SGO1 siRNA in the absence (g) or presence (h) of 
nocodazole and reversine (500 nM). Kinetochore intensities are relative to LAP-BUBR1WT (d) or  mock 
treated Flp-in HeLa (k) cells, and at least 10 cells were quantified for each condition per experiment. 
Quantifications show the mean data (±SD) from 3 (d) or 5 (k) independent experiments (see 
Supplementary Table 2). Asterisks indicate significance (student t-test, unpaired). ****: p<0.0001. 
Insets display magnifications of the boxed regions. Bars, 5 μm. 
Supplementary Figure 2. Characterisation of KNL1 antibodies and cell lines used in this study. (a) 
Representative images and (b-d) quantification of relative kinetochore intensities of indicated 
antigens in nocodazole-arrested Flp-in HeLa cells transfected with mock or PP2A-B56 siRNA (b), or 
with KNL1 siRNA and induced to express LAP-KNL1WT or LAP-KNL12SA (c, d). (e) KNL1, GFP, Transferrin 
Receptor Protein 1 (TFR1) immunoblot of whole-cell lysates from nocodazole-arrested Flp-in HeLa 
cells transfected with mock or KNL1 siRNA and induced to express the indicated LAP-KNL1 mutants. 
Boxes on left show molecular mass standard. Mw, molecular weight. Westerns are representative of 
2 independent experiments. (f) Quantification of relative kinetochore intensities of LAP-KNL1 in 
nocodazole-arrested Flp-in HeLa cells expressing KNL1WT or indicated KNL1 mutants. Insets display 
magnifications of the boxed regions. Bar graphs display mean fold-change in kinetochore intensities 
(±SD) relative to mock transfected (b) or LAP-KNL1WT cells (c, d, f), from 3 (c, d), 4 (b), or 7 (f) 
independent experiments with at least 10 cells quantified for each condition per experiment (see 
Supplementary Table 2). Asterisks indicate significance (student t-test, unpaired). NS: not significant, 
*: p<0.05, ****: p<0.0001. DNA (DAPI) is shown in blue. Bars, 5 μm. 
Supplementary Figure 3. Aurora B activity and KNL1-PP1 interaction controls SAC silencing 
downstream of PP2A-B56. (a-f) Time-lapse analysis of duration of mitotic arrest in nocodazole-
treated Flp-in HeLa cells transfected with mock siRNA (a, c), PP2A-B56 siRNA (b, d), or expressing 
LAP-BUBR1WT (e) or LAP-BUBR1KARD (f).  Cells entered mitosis in the presence of DMSO, reversine 
(125-500 nM), AZ-3146 (2.5-0.63 M), and ZM-447439 (2M), as indicated. (g) MAD2, CDC20, 
Tubulin and BUBR1 immunoblots (IB) of whole-cell lysates and CDC20 immunoblots of 
immunopurified (IP) MAD2 from mitotic Flp-in HeLa cells transfected with KNL1 siRNA and 
expressing the indicated LAP-KNL1 mutants. Nocodazole-arrested cells were treated with MG132 
and DMSO or reversine (500 nM). Band intensity of CDC20 in MAD2 IPs is indicated. Boxes on left 
show molecular mass standard. Mw, molecular weight. Westerns are representative of 3 
independent experiments. (h) Time-lapse analysis of duration of mitotic arrest in nocodazole-treated 
Flp-in HeLa cells transfected with KNL1 siRNA and expressing the indicated LAP-KNL1 constructs. 
Cells entered mitosis in the presence of 500 nM of reversine. Cells were additionally transfected with 
mock, MAD2 or BUBR1 siRNAs. Graphs show cumulative data from 50 cells per treatment from one 
experiment, which is representative of 2 independent experiments. 
Supplementary Figure 4. Kinetochore PP1 antagonises SAC protein accumulation at kinetochores 
without affecting kinetochore kinase activity.  
(a) Quantification of relative kinetochore intensities of indicated antigens from nocodazole-treated 
Flp-in HeLa cells expressing BUBR1WT or BUBR1KARD. (b) Quantification of chromosomal alignment in 
Flp-in HeLa cells expressing LAP-KNL1WT or LAP-KNL12A and transfected with mock or PP2A-B56 
siRNA. At least 100 cells were quantified for each condition per experiment and data is the mean of 
3 independent experiments (see Supplementary Table 2). (c) Quantification of relative kinetochore 
intensities of indicated antigens from nocodazole-treated Flp-in HeLa cells expressing LAP-KNL1WT or 
LAP-KNL12SA and treated with mock or B56 siRNA, as indicated. (d) GST and p-MELT immunoblots of 
purified GST-KNL1-M3 or GST-KNL1-A3 incubated in a kinase reaction -/+ MPS1 for 60 mins to 
phosphorylate the MELT motifs. KNL1-M3 contains a KNL1818-1051 fragment that incorporates 3 MELT 
motifs and the A3 version is the same fragment but with critical residues in each MELT motif 
mutated to alanine 22. Westerns are representative of 2 independent experiments. (e-j) 
Representative images (e, g, i) and quantification (f, h, j) of relative kinetochore intensities of 
indicated antigens from nocodazole-treated Flp-in HeLa cells expressing various LAP-KNL1 mutants 
and treated with nocodazole, DMSO, reversine (500 nM) or MG132, as indicated. (k, l) 
Representative images of indicated antigens on metaphase aligned kinetochores in Flp-in HeLa cells 
expressing various LAP-KNL1 mutants. (m) Quantification of relative kinetochore intensities of 
indicated antigens from nocodazole-treated Flp-in HeLa cells expressing various KNL1 mutants. The 
p-Aurora B (Thr232) and p-MPS1 (Thr676) antibodies are directed against the activation loop 
phosphorylation sites. Only early prometaphase cells were characterised for p-MPS1 (Thr676) 
antibody, for reasons stated previously 40.  The p-CENP-T (Ser47) site is a characterised kinetochore 
CDK1 substrate 41. All kinetochore intensities are relative to the untreated wild type controls in each 
experiment. At least 10 cells were quantified for each condition per experiment and quantifications 
show the mean data (±SD) from 3 (a, f, j, m), 4 (c) or 5 (h) independent experiments (see 
Supplementary Table 2). DNA (DAPI) is shown in blue. Insets are magnifications of the boxed regions. 
Asterisks indicate significance (student t-test, unpaired). NS: not significant, *: p<0.05, **: p<0.01, 
***: p<0.001, ****: p<0.0001. Bars, 5 µm. 
Supplementary Figure 5. Negative feedback and SAC silencing is unaffected by high nocodazole or 
SGO1 depletion. (a, b) Quantifications of relative kinetochore intensities of indicated antigens from 
Flp-in HeLa cells (a), LAP-BUBR1WT or LAP-BUBR1KARD-expressing cells (b) treated with a high dose of 
nocodazole (3.3M) 35. Different mitotic phases where determined by nuclear morphology; 
Prophase (Pro), early mitosis (EM; defined as dispersed lightly condensed chromatin) and late 
mitosis (LM; highly condensed chromatin balls typical of nocodazole-arrested cells). Insets display 
magnifications of the boxed regions. All kinetochore intensities are relative to the maximum signal in 
each experiment, except in b, which are relative to the prophase signal in LAP-BUBR1WT cells. The 
bar graphs show the mean data (±SD) from at least 10 cells for each condition from 1 experiment, 
which is representative of 2 experiments. (c) Quantification of relative LAP-BUBR1 kinetochore 
intensities from time-lapse images of LAP-BUBR1WT cells transfected with mock or SGO1 siRNA 
arrested in prometaphase with nocodazole and MG132, prior to treatment with reversine (1 µM) 
and ZM-447439 (2 µM) for the indicated times. At least 15 cells were quantified for each cell line per 
experiment and quantifications show the mean data (±SD), relative to the 0 min timepoint, from 3 
independent experiments. Bars, 5 μm. 
Supplementary Figure 6. Full scans of all western blot images. 
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